BioSpace News Archive

Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 24, 2020, pursuant to the Agreement and Plan of Merger by and among Melinta, Toronto Transaction Corp. (“Purchaser”) and Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) dated as of June 4, 2020 (the “Merger Agreement”), it had terminated the previously announced cash tender offer to acquire all of the outstanding shares of common stock of Tetraphase (the “Offer”).

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has commenced concurrent underwritten public offerings of $20,000,000 in shares of its common stock (the “Shares”) and $60,000,000 aggregate principal amount of convertible senior notes due 2025 (the “Notes”).

Magenta Therapeutics, Inc., a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more patients, announced that it has commenced an underwritten public offering of $60 million of its common stock.

Sinovac Biotech Ltd. ( “Sinovac” or the “ Company”)(Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced the China National Medical Products Administration (or NMPA) issued a product license for its quadrivalent Influenza vaccine (or QIV).

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

While studying the genetics of the androgen receptor in male pattern baldness, a team of scientists discovered a possible breakthrough treatment for COVID-19.

IBEX Technologies Inc. reported its financial results for the nine months ended April 30, 2020.

Digirad Corporation (Nasdaq: DRAD; DRADP) (“Digirad” or the “Company”), a diversified holding company with three divisions: Healthcare, Building & Construction, and Real Estate & Investments, today announced that its management team will be presenting at the Sidoti Inaugural Virtual Microcap Conference, on Tuesday, June 30 th . Digirad’s main presentation is scheduled for 12:15 pm ET, in Virtual Estate Room #1. Investors will be able t

Vaxart, Inc. (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it has joined the broad-market Russell 3000 Ò Index at the conclusion of the 2020 Russell indexes annual reconstitution, effective Monday, June 29 th 2020 after the U.S. market opening. Annual Russell indexes reconstitution captures t

Gritstone Oncology (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the Gritstone management team will host an investor teleconference and webcast on July 13, 2020 at 8:00 a.m. ET to present data from the ongoing Phase 1 studies of its immunotherapy product candidates GRANITE and SLATE. Phase 2 study plans will also be dis